Adage Capital Partners
CRL icon

Adage Capital Partners’s Charles River Laboratories CRL Stock Holding History

Adage Capital Partners’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48.4M Sell
213,480
-42,529
-17% -$7.57M 0.07% 290
2026
Q1 		$44.2M Sell
256,009
-55,648
-18% -$10.3M 0.07% 280
2025
Q4 		$62.2M Buy
311,657
+177,122
+132% +$32.1M 0.09% 207
2025
Q3 		$21M Buy
134,535
+89,535
+199% +$14.2M 0.03% 454
2025
Q2 		$6.83M Buy
+45,000
New +$6M 0.01% 675
2024
Q3 		– Sell
-42,269
Closed -$8.73M – 887
2024
Q2 		$8.73M Sell
42,269
-44,914
-52% -$10.2M 0.02% 631
2024
Q1 		$23.6M Sell
87,183
-66,872
-43% -$16M 0.04% 404
2023
Q4 		$36.4M Buy
154,055
+44,342
+40% +$8.72M 0.08% 271
2023
Q3 		$21.5M Buy
109,713
+98,565
+884% +$20.2M 0.05% 378
2023
Q2 		$2.34M Buy
11,148
+3,343
+43% +$665K 0.01% 733
2023
Q1 		$1.58M Sell
7,805
-43,995
-85% -$9.97M ﹤0.01% 780
2022
Q4 		$11.3M Buy
+51,800
New +$11.3M 0.03% 607
2022
Q3 		– Sell
-52,900
Closed -$11.3M – 1060
2022
Q2 		$11.3M Buy
52,900
+40,200
+317% +$9.82M 0.03% 640
2022
Q1 		$3.61M Sell
12,700
-41,100
-76% -$12.7M 0.01% 858
2021
Q4 		$20.3M Sell
53,800
-800
-1% -$311K 0.04% 456
2021
Q3 		$22.5M Sell
54,600
-800
-1% -$332K 0.04% 408
2021
Q2 		$20.5M Buy
+55,400
New +$18.5M 0.04% 452
2018
Q1 		– Sell
-150,000
Closed -$16.4M – 727
2017
Q4 		$16.4M Buy
150,000
+50,000
+50% +$5.44M 0.04% 465
2017
Q3 		$10.8M Buy
+100,000
New +$10.3M 0.03% 546
2016
Q1 		– Sell
-39,500
Closed -$3.17M – 692
2015
Q4 		$3.17M Buy
+39,500
New +$2.85M 0.01% 632
2015
Q3 		– Sell
-200,000
Closed -$14.1M – 719
2015
Q2 		$14.1M Buy
+200,000
New +$14.8M 0.04% 488
2014
Q2 		– Sell
-614,268
Closed -$37.1M – 700
2014
Q1 		$37.1M Buy
614,268
+110,000
+22% +$6.41M 0.1% 248
2013
Q4 		$26.7M Buy
504,268
+50,000
+11% +$2.51M 0.07% 331
2013
Q3 		$21M Sell
454,268
-50,000
-10% -$2.29M 0.06% 364
2013
Q2 		$20.7M Buy
+504,268
New +$21.6M 0.06% 350

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Adage Capital Partners's CRL Position: Q2 2026 in Review

Adage Capital Partners reduced its Charles River Laboratories (CRL) stake by 17% in Q2 2026, selling an estimated $7.57M and leaving 213,480 shares worth $48.4M. The position accounts for 0.07% of the portfolio, ranked #290.

Adage Capital Partners first reported a position in CRL in Q2 2013 and has held it in 25 quarters since. The position peaked at $62.2M in Q4 2025. 568 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Adage Capital Partners held 213,480 shares of Charles River Laboratories worth $48.4M as of Q2 2026.
  • Adage Capital Partners sold 42,529 Charles River Laboratories shares in Q2 2026, an estimated $7.57M.
  • Charles River Laboratories made up 0.07% of Adage Capital Partners's portfolio in Q2 2026, its #290 holding.
  • Adage Capital Partners first reported a position in Charles River Laboratories in Q2 2013 and has held it in 25 quarters since.
  • Adage Capital Partners's Charles River Laboratories position peaked at $62.2M in Q4 2025.
  • 568 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.